These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 29880396)
1. A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy. Alan O; Telli TA; Ercelep O; Hasanov R; Simsek ET; Mutis A; Ones T; Kaya H; Yumuk PF Curr Probl Cancer; 2019 Aug; 43(4):308-311. PubMed ID: 29880396 [TBL] [Abstract][Full Text] [Related]
2. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380 [TBL] [Abstract][Full Text] [Related]
3. A Case of Metaplastic Squamous Cell Carcinoma of the Breast that Showed a Pathological Complete Response After Neoadjuvant Chemotherapy with Weekly Paclitaxel. Noro A; Ishitobi M; Hanamura N; Kashikura Y; Yamashita M; Kozuka Y; Saito K; Mizuno T; Ogawa T Am J Case Rep; 2022 Jan; 23():e935035. PubMed ID: 35017459 [TBL] [Abstract][Full Text] [Related]
4. [A Case of Metaplastic Squamous Cell Carcinoma of the Breast Diagnosed after Neoadjuvant Chemotherapy]. Ishikawa N; Saimura M; Koga K; Anan K; Mitsuyama S; Tamiya S Gan To Kagaku Ryoho; 2018 Jul; 45(7):1101-1103. PubMed ID: 30042281 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety. Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989 [TBL] [Abstract][Full Text] [Related]
6. [A case of aggressive primary squamous cell carcinoma of the breast refractory to preoperative neoadjuvant chemotherapy]. Uchida N; Ishiguro K; Suda T; Nishimura M Gan To Kagaku Ryoho; 2009 Dec; 36(13):2619-22. PubMed ID: 20009466 [TBL] [Abstract][Full Text] [Related]
7. Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma. Chen SC; Chang HK; Lin YC; Cheung YC; Tsai CS; Leung WM; Hsueh S; Chen MF Onkologie; 2005 Jun; 28(6-7):339-44. PubMed ID: 15933422 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study. Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676 [TBL] [Abstract][Full Text] [Related]
9. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750 [TBL] [Abstract][Full Text] [Related]
10. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539 [TBL] [Abstract][Full Text] [Related]
11. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263 [TBL] [Abstract][Full Text] [Related]
12. Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m Kojima Y; Kawamoto H; Nishikawa T; Hayami R; Shimo A; Haku E; Akiyama K; Tsugawa K Clin Breast Cancer; 2018 Oct; 18(5):374-379. PubMed ID: 29452759 [TBL] [Abstract][Full Text] [Related]
13. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer. Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474 [TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566 [TBL] [Abstract][Full Text] [Related]
15. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039 [TBL] [Abstract][Full Text] [Related]
16. A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response. Yamaguchi J; Akashi-Tanaka S; Fukutomi T; Kinosita T; Iwamoto E; Takasugi M Breast Cancer; 2006; 13(1):100-3. PubMed ID: 16518069 [TBL] [Abstract][Full Text] [Related]
17. [A case of giant advanced ulcerative breast cancer managed with epirubicin and cyclophosphamide followed by weekly paclitaxel]. Moriya T; Fukatsu K; Ueda S; Iwaya K; Osaki A; Yamamoto J Gan To Kagaku Ryoho; 2010 May; 37(5):907-10. PubMed ID: 20495326 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148 [TBL] [Abstract][Full Text] [Related]
19. [A case of breast adenocarcinoma changed to squamous cell carcinoma after neoadjuvant chemotherapy]. Minagawa M; Kanzaki M; Takano Y; Nishikawa T; Deie K; Minami Y; Maeda M; Teshima S Gan To Kagaku Ryoho; 2012 Jul; 39(7):1111-4. PubMed ID: 22790049 [TBL] [Abstract][Full Text] [Related]
20. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]